Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-957 multiple-dose study in Alzheimer's disease
NCT02220738Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing ABT-957 with Placebo (2 arms). Primary endpoints: Pharmacokinetic evaluation of the two ABT-957 diastereomers at Day 7 and Number of subjects with adverse events at 7 months. Started Sep 2014; status: terminated.
02
Drugs
alicapistat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02220738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220738.